Chiron, Inhale antibiotic deal

CHIR and INHL partnered to develop an inhalable dry-powder formulation of CHIR's Tobi tobramycin to treat Pseudomonas aeruginosa infections in cystic fibrosis patients. CHIR will be responsible for clinical development and marketing, and INHL will develop the tobramycin formulation and manufacture the resulting product for clinical and commercial uses. INHL will receive R&D funding, milestones and royalties. The companies also will research other antibiotics for inhalable formulations using INHL's Inhance pulmonary delivery technology. ...